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INTRODUCTION
Cloning genes has come to be a matter of routine. If the sequence of the encoded protein is known, a cDNA can usually be isolated from a library in 2-3 days, or amplified in toto by PCR in a matter of hours. The cloning of the gene itself follows as a formality. In the case of most human (and mouse) genes, cloning will, in large measure, fall by the wayside as the complete genomic sequence becomes known.
But what does one do if the sequence of the protein in question is unknown -and unknowable -even after exercise of all 'conventional' tools at the investigator's command? What if the protein cannot be purified? What if the cDNA cannot be cloned from expression libraries?
In sum, what if a mutant phenotype alone gives clue to the very existence of the gene? The level of complexity involved in finding a gene known only by phenotype is far greater than that which attends the cloning of a gene encoding a known (or knowable) protein product. One may expect that years will elapse before such a gene can be identified. Nonetheless, the basic or practical importance of the gene may justify an unbridled attempt to find it. For this reason, extraordinary efforts were made to find the mutations (and hence, the mutant genes) responsible for cystic fibrosis, Huntington's disease, Duchenne's muscular dystrophy, certain familial forms of cancer, obesity, and many other phenotypes of exceptional interest.
The search for Lps was a story in the same mold. It was fueled by dreams of a conceptual leap in immunology. In cloning Lps, we hoped to grasp the mechanism by which endotoxin activates macrophages, leading to shock in Gram-negative sepsis. More generally, we hoped to understand how macrophages and granulocytes could perceive microbes at all, for little was known of the sensing mechanism utilized by these cells.
The Lps locus of mice remained a phenotypic puzzle for 33 years. The puzzle came into being in 1965, with the discovery that C3H/HeJ mice were highly resistant to LPS. 1 It ended in 1998, with the discovery of the genetic defect in these animals. 2 The search for Lps consumed the energies of seven postdoctoral fellows, four technicians and one senior investigator for five of these years, between the spring of 1993 and the summer of 1998, largely to the exclusion of all other work in the laboratory. Three million dollars were expended in cloning the gene. Yet there is no doubt that the effort, risk, and monetary cost were justified. The new-found identity of Lps has opened the way to many new lines of scientific inquiry. It has enlightened understanding of how we, as vertebrates, sense infection. It has revealed the principal receptors of innate immunity and placed them on a par with the receptors of acquired immunity. It has allowed us to search for new approaches to the blockade of inflammation, and also, to search for defects in microbial sensing that might explain immunodeficiency disorders.
The endotoxin field has now largely absorbed the cloning of Lps, and has moved forward. Our recollections are presented here to promote broad understanding of how this gene was cloned, and also, 'that time may not draw the color from what man has brought into being...'. 3
THE BEGINNINGS: FAILED ASSAULTS
Today, Lps is rarely mentioned by that name: it is the Toll-like receptor 4 gene, Tlr4. It is never mentioned without concomitant utterance of the mantra 'innate immunity'. There were many potential gains to be had in finding the gene, and insofar as bacterial endotoxin stimulates cells of the innate immune system, we hoped to achieve a broad comprehension of exactly how innate immune activation occurs. But the most tangible and proximal incentive to pursue Lps was the chance of solving the central problem of endotoxin biology: the question as to how LPS, the most powerful pro-inflammatory agent known, evokes a signal.
The 1990 discovery that CD14 acts as the principal receptor for LPS on the surface of mononuclear cells 4 was a breakthrough that helped to concentrate interest in Lps, this because Lps was believed to encode the next protein in the biochemical pathway required for LPS responses. The effect of antibodies against CD14 5, 6 and the phenotype imparted by the CD14 knockout mutation 7 (both of which markedly impede LPS signal transduction), convinced all serious workers in the endotoxin field that CD14 must be an essential part of the signaling pathway. Yet, as was often recounted, the fact that CD14 lacked a cytoplasmic domain strongly suggested the existence of a co-receptor, then still unidentified.
The positional attack on the Lps locus was an approach of last resort. Before trying to clone Lps the 'hard' way, we tried to clone it the 'easy' way. Many other workers tried as well, but because none were successful, there is little for the historian to follow in the way of a paper trail. During the years between 1990 and 1993, we ourselves attempted to identify differences between C3H/HeJ and C3H/HeN macrophages at the level of proteins and cDNA clones. These efforts, though never built to the scale of the positional attempt that was to follow, were both time-consuming and fruitless. Polyacrylamide gel electrophoresis was used to examine cells and membrane fractions from the two strains of mice. We cross-immunized mice of each strain with cells derived from the opposite strain, hoping to raise an antiserum with specificity for cells from one strain or the other. Both approaches failed, for reasons that are all too obvious today. Several groups attempted to find a binding partner for CD14, which might act to transduce the LPS signal across the membrane. Co-precipitation experiments, cross-linking experiments, and use of the two-hybrid system were all applied to the problem without success. Two expression cDNA cloning methods for the isolation of Lps were also devised in our laboratory. Each depended upon the use of immortalized C3H/HeJ macrophages.
At the Annual Conference of the Upper Rhine Universities {1}, I formed two scientific contacts that were to influence our work for the next 8 years. First, I became familiar with the work of Paola Ricciardi-Castagnoli, who had then recently developed a technique for the routine immortalization of mouse macrophages and dendritic cells. It depended upon retrovirally mediated transfection of the target cell population, using a vector that carried the v-myc oncogene. 8, 9 Paola had, in fact, already created macrophage lines from C3H/HeJ mice. Her poster was most memorable, since it described exactly what seemed to be needed. She graciously agreed to give some of these cells to us (and later, immortalized a second line derived from F1 animals created by mating C3H/HeJ mice to BALB/c mice).
Second, I held the first of innumerable conversations about Lps with Chris Galanos and Marina Freudenberg, who were immensely curious about the nature of this gene: in particular, about the nature of the difference between mutations in the C3H/HeJ and C57BL/10ScCr strains of mice. In 1977, 10 Coutinho and colleagues had reported that B cells derived from C57BL/10ScCr mice were unresponsive to LPS, and the following year, 11 convincingly ascribed this trait to a novel mutation at the Lps locus, noting a strictly recessive pattern of inheri-tance rather than co-dominant transmission, which had been reported for the Lps d allele. [12] [13] [14] This extremely important piece of work was later to play a crucial part in sealing the identity of Lps and Tlr4 and, in 1990, Chris and Marina were the first to impress me with the importance of these animals. Then and later, we spoke for many hours about the two strains of mice: specifically, about the relative resistance of the two strains to LPS, and about the different effect of infectious agents in modulating resistance to LPS: [15] [16] [17] a phenomenon that escapes complete understanding even today. They would, in coming years, examine the possibility that CD14 expression might be aberrant in C3H/HeJ mice, and would find that it clearly was not. 18 Their insight into the system of LPS response was always valuable to us and, during the years that followed, they provided us with macrophage RNA and genomic DNA from the C57BL/10ScCr mice: materials that we used frequently in attempting to exclude or confirm candidate genes. I returned to Dallas, and set about working with Paola's cells. After much experimentation, we found that a gene gun loaded with DNA-coated tungsten pellets offered the most efficient means of transfecting these macrophages. cDNA produced from human monocytes was co-transfected together with a reporter construct (a chloramphenicol acetyltransferase [CAT] coding sequence flanked by the TNF promoter and 3′-UTR) which would permit us to detect restoration of LPS signaling. An ample expression library was screened as a series of divided 'pools', but in no pool could we measure LPS-induced CAT activity.
A second attempt at cDNA cloning was made using a neo gene, again flanked by the TNF promoter and 3′-UTR. Véronique Kruys, an energetic and skillful postdoctoral fellow in my laboratory, attempted to rescue the responsive phenotype through G418 selection of LPSinduced, transfected cells. This attempt also failed.
The immortalized F1 hybrid cells produced by Paola Ricciardi-Castagnoli were used in a final attempt to clone Lps the 'easy way'; this time, by insertional mutagenesis. Reasoning that the co-dominant Lps d allele probably represented a loss-of-function mutation, we attempted to destroy the remaining active copy of the gene through retroviral insertion. Retrospectively, it is quite clear that this approach might have worked, and most probably would have worked had it been attempted with present-day reagents and equipment. But, in 1992, we lacked the means to monitor the efficiency of retroviral infection, and the means to adequately screen for destruction of the normal allele.
And so the Lps gene remained at large. Our desire to clone it grew steadily, building to form the obsession that was ultimately required for success. In those days, there were many guesses concerning the protein encoded by Lps, and only one of these was fundamentally correct ( Table 1 ). As we had previously determined that TNF plays an important role in endotoxicity, 19 and as it was known that LPS toxicity is dependent upon cells of hematopoietic origin 20 -specifically macrophages, 21 the essential role of macrophages and TNF production in LPS sensing was accepted dogma. TNF seemed the ideal end-point to follow in any study of endotoxicity, and the macrophage seemed the correct cell for confirmation of any candidate that might emerge. The notion that Lps encoded a co-receptor specific for LPS signaling was particularly appealing. But why had such a co-receptor not been isolated?
THE METHOD OF LAST RESORT
Positional cloning is a winner-take-all game. Once the target gene is discovered, most of the work that has been done by unsuccessful competitors is for naught. In this way, positional cloning differs from most other scientific ventures, wherein discoveries of importance are made along the way, and in which even if one is not the first to reach the goal, much has been learned (and many papers published). If we were to expend the effort needed to clone Lps, we wanted to be the first to find it, and we were aware that many others in this field were challenged by the same scientific problem. We considered the possibility that other approaches, such as retrograde analysis of signal transduction pathways, might lead to the identification of a coreceptor (and, hence, the gene itself). Or, as it might happen, a cDNA cloning project, pursued with sufficient vigor and skill, might indeed disclose the gene. The basic principles of positional cloning are enshrined in the three steps that every such project must traverse ( Fig. 1 ). First (in the 'genetic mapping' phase), the location of a mutation must be circumscribed to a small inter- Fig. 1 . The general strategy of positional cloning, and its specific application in the search for Lps. The Lps d mutation was initially confined to chromosome 4 (orange) by Watson and colleagues. 12 This assignment in itself eliminated approximately 90% of the genome from consideration. The further confinement of Lps d to a position between Mup-1 and Ps loci in the central third of the chromosome 13 eliminated approximately 99% of the genome. Subsequent genetic mapping, carried out in conjunction with physical mapping by Poltorak et al., 25 excluded 99.9% of the genome, placing Lps d within an interval 2.6 x 10 6 bp in length. Within the critical region, schematically shown here as an array of 66 overlapping BACs spanning the interval delimited by markers B and 83.3, two proximally placed BACs (orange) were found to harbor Tlr4. Tlr4 (orange) was the sole authentic gene present in the critical region, although a small part of the Pappa gene protruded into the region, and several pseudogenes (gray) were found. Tlr4 is 16 kbp in length. With its identification as the sole candidate, 99.9995% of the genome was excluded from consideration. Upon sequencing the coding region of Tlr4, a C → A base transversion (orange) was identified in the third exon of the gene. This mutation specified the substitution of a histidine for an invariant proline within the cytoplasmic domain of the receptor. The nucleotide was mutated only in C3H/HeJ mice, and no exception to the contrary has been found, despite the fact that complete coding sequence data have now been published for 37 Mus musculus strains. 74 val within the genome. In general, this is accomplished through measurement of meiotic cross-over frequency between the mutation of interest and markers proximal and distal to that locus. This involves phenotypic and genotypic study of hundreds or thousands of F2 mice, generated by crossing and back-crossing animals with the mutation of interest. Once the gene has been 'boxed' between closely spaced markers, all DNA spanning the region is cloned in large, overlapping pieces, using YACs (yeast artificial chromosomes, which may package over 1 Mbp of DNA) or BACs (bacterial artificial chromosomes, which may package as much as 400 kbp of DNA). In this, the second phase of the project ('physical mapping'), more markers are identified, and placed in order with respect to one another. The mutation is further confined if possible. The maximum size of the genomic interval that might contain the gene is determined by electrophoretic methods, or by fluorescence in situ hybridization (FISH), in which BAC clones are permitted to form duplexes with interphase chromosomes. The final phase of the project ('gene identification') involves the examination of every gene that lies within the interval, and exclusion of candidates by sequencing until the mutation is found. Candidates may be found using several methods too detailed for present discussion, but exon trapping, direct selection, and shotgun sequencing are the most commonly used, and shotgun sequencing has become the most powerful tool of the three.
My awareness of the positional cloning option grew from several sources. A clear presentation of the technique -and its many pitfalls -was made to me through contact with other HHMI investigators. In 1991, at one of the last HHMI investigator retreats to be held at the NIH Cloisters, I asked Francis Collins, then an HHMI investigator himself and recent conqueror of the cystic fibrosis gene, about positional cloning as a potential tool to find Lps. His reply was polite and thoughtful, but not encouraging. Given the size of the existing genetic confinement (more than 15 cM separated the nearest flanking classical markers, Mup-I and Ps), far more work would be required to narrow the position of the gene {2} and that, he felt, would be a particularly tough prospect given the density of markers in the mouse genome (then very sparse).
Nonetheless, during the late 1980s and early 1990s, it seemed that every week brought the identification of another gene, cloned by positional methods. The Huntington's disease gene, the gene for familial amyotrophic lateral sclerosis (ALS), and the Duchenne's gene were among these. The power of the approach was not lost on us, nor was the relative ease of its application in mice, given that crosses could be wilfully produced, and phenotype scored with speed and objectivity.
Ironically, we found our strongest inspiration for the pursuit of a positional approach to Lps in the earlier cloning efforts of our competitors. Emil Skamene, a dis-tinguished worker in the genetics of host resistance, was first introduced to me on Sunday, March 8, 1987, when we had lunch together at a meeting of the Canadian Society for Immunology {3}. He showed a great deal of curiosity about the Lps locus, much in tune with his interest in other mouse mutations affecting immune competence. Five years later, at the International Congress on the Regulation of Leukocyte Production and Immune Function {4}, I was thrilled to hear him present the story of the cloning of the Nramp-1 gene (formerly known as the Lsh/Ity/Bcg locus). The simplicity of the approach was indeed alluring, as was the fact that the mutation had been confined to a mere 50 kbp of DNA: by present standards, next to nothing, though then, still a challenging interval to explore {5}.
By mid-1993, the positional route to finding Lps appeared the surest, albeit perhaps the most arduous road to travel. While we had no illusions that positional cloning would be a romp, neither had we reason to suspect that finding the gene would evolve as one of the most formidable problems ever confronted. The density of markers throughout the mouse genome had increased dramatically during the preceding year, largely as the result of mapping efforts by Eric Lander's group at the Whitehead Institute, whose initial map, published in 1992, had contained only 317 markers. 22 By early 1994, clusters of markers, usually five or ten deep, were arranged at intervals of 1 cM along mouse chromosome 4. These markers, in the form of primer pairs capable of amplifying microsatellites, were soon to be made available on the World Wide Web {6}.
To be sure, we faced serious short-comings, both in terms of experience and matériel. We had never cloned anything positionally before. We had no computer of our own with which to bear the monstrous computational burdens that were shortly to befall us. We had no automated sequencer and, for the first year of gene identification work, trapped exons and direct selection clones were sequenced by hand. Usually, beginning early each morning with cups of strong coffee, two of us would read the sequence together from X-ray film, one dictating bases and the other typing them into a computer, until by noon, several thousand bases had been recorded. Often Betsy Layton, my Administrative Assistant, would participate in reading and transcribing sequence (as she participated in so many other aspects of the project).
Beyond material short-falls, we were plagued by a lack of academic support for our effort. HHMI was never particularly friendly to our cause. The Institute steadfastly refused to fund the purchase of a sequencer for us at any point during the project though I pleaded repeatedly for this rather modest accommodation, and though the tool was utterly indispensable for our work {7}. Local (UT Southwestern) politics did not help us either. Among the faculty were individuals who felt that molecular genetics of this sort lay within their purview alone. They made their opinions known to those who funded us.
But such thoughts were not in our minds at the inception of the project. Suffice it to say that, unprepared though we might have been, we plunged into the project with optimism and alacrity, confident that our conversance with genetics and undoubted familiarity with the vagaries of the LPS response would see us through.
WERE WE TOO LATE EVEN TO BEGIN?
Committed to clone the gene by this fresh approach, we began to cross C3H/HeJ mice with SWR animals in the spring of 1993, to generate F1 mice, and ultimately, F2 mice, that would permit us to map the locus.
Around every corner was the prospect that another laboratory might clone the gene, ending our project perforce. The pain that this would cause us grew in proportion to the investment of time and effort that had been applied to the project. By that measure, our mutual devotion to the project became clear quite early in the game. On August 8, 1993, Stefanie Vogel informed me that the end was approaching. She described a commanding lead held by Emil Skamene and his colleagues, among them the project leader, Danielle Malo {8}. Through an intermediary, she had learned that the Canadian group was 'already 800 meioses into the project'. Whereupon Stefanie, with an implicit sigh of resignation, suggested to me that there would be 'other genes to clone'.
Since Stefanie had first written to me in 1985, we had been on friendly terms, and I knew her as an honest and forthright person. At my invitation in 1992, she had contributed a chapter to a monograph that I had edited on TNF, 23 in which she thoroughly reviewed the discovery of Lps, and thoughtfully considered many possibilities concerning its function. The chapter itself had been a guiding light to me, and was required reading for all new postdoctoral fellows. Stefanie had also shown genetic inclinations toward the solution of the Lps problem, and had confined the gene to a 5.5 cM region surrounding the b locus {9}. 24 Periodically, I inquired as to whether she had heard of any progress in identifying Lps, a gene that interested her as much as it interested me. Her conviction that the gene would soon be cloned was dispiriting indeed. She herself did not give up, however, nor did we.
CHRISTOPHE VAN HUFFEL AND THE FIRST YEAR
A talented Belgian molecular biologist with a strong background in yeast genetics, Christophe Van Huffel was first introduced to the laboratory by Véronique Kruys, whose earlier efforts to find Lps have already been mentioned. He arrived in Dallas on August 15th, 1993, by which time we had already crossed C3H/HeJ mice to animals of the SWR strain, yielding an F1 gener-ation. The choice of a mating partner for C3H/HeJ had been based more upon the fact that SWR animals were present in the lab than upon any careful planning. We never had cause to regret the use of a Mus musculus strain, however, as we wished both then and later to maximize the frequency of crossing over, confident that the density of polymorphic markers would be adequate whether or not we chose a genetically distant mating partner for C3H/HeJ. A Mus musculus cross is the best way to achieve high cross-over frequency, and our judgement was soon vindicated. Christophe worked with energy and enthusiasm to generate F2 mice. But, from the very start, he encountered difficulties, as hepatitis swept though the colony, decimating those animals that were born, and sharply diminishing the frequency of live births. Somehow, he managed to produce 493 animals for assay: far fewer than we would have liked, but perhaps enough, we felt, to confine Lps to a reasonably small interval {10}. Then and later, mindful of the consequences that a single mix-up might have on our localization of the gene, we took extraordinary precautions to label mice, tissue, and assay samples. Any ambiguity was cause to discard a sample. Two observers were present at all stages of the process. In the end, we would have few events -perhaps as few as three or four crossovers -upon which to rely in assigning the position of the gene. Hence, we must have absolute confidence in each one of them.
Using two assays of LPS responsiveness to examine the phenotype of the F2 mice (B cell mitogenesis and macrophage TNF production) Christophe mapped the gene with respect to eleven markers, covering much of mid-chromosome 4. 25 The closest flanking markers were separated from each other by 15 cross-over events in our panel of 493 meioses. This might normally correspond to physical separation of about 3 Mbp. In the event, we later determined that the physical size of this initial zone of confinement was closer to 6 Mbp.
Christophe immediately set about to isolate YAC clones covering the critical region, using all of the markers in the area at once to secure them, and concentrating on the proximal half of the interval, since only a single crossover event separated the proximal marker from Lps d . He was successful, producing the first physical map of the region: a map which was to undergo many revisions and to grow in complexity over the years that followed ( Fig. 2A-F ). BACs, still something of a novelty, were to be employed as the mainstay of our work in months to come, as they offered many technical advantages compared with YACs.
Alexander Poltorak quickly fragmented the YAC clones, produced shotgun libraries, and proceeded to identify 50 or more novel microsatellite markers within the critical region. This was achieved by hybridization screening, as we had not yet the means to engage in high through-put sequence analysis of the region. But, as microsatellites are rather easy to recognize on manual sequencing gels, and as we had actively screened for such clones, we were not at a serious disadvantage. About one in six of the microsatellite markers differed discernibly with respect to length when we used primers to amplify them from genomic DNA of C3H/HeJ and SWR mice. These markers, then, were used as tools to further narrow the confinement of the locus. One of the new markers, termed 83.3 (because it was the third microsatellite derived from a YAC containing marker D4Mit83) became the new distal boundary of the critical region, separated from Lps d by three cross-over events in 493 meioses. Though we would have liked to narrow the The search for Lps: 1993-1998 275 27 who employed deletion mapping for this purpose. Diamonds indicate hypothetical distribution of 16 cross-over events detected in the region (three were later discarded as unreliable). Only one cross-over was known to exist between D4Mit82 and Lps d ; hence, our attention was focused on the proximal half of the interval. A framework of YAC (top) and BAC (bottom) clones was assembled within the region. New markers (with alphanumeric designations) were assigned based on sequences identified in shotgun cloned libraries prepared from the YACs. (B) By February 1, 1996, many more BAC clones had been identified, and were placed astride an equally dense framework of YAC clones. The novel marker 83.3 had become the distal border of the contig. The classical marker D4Mit325 had become the proximal border. FISH studies (top) had revealed the physical size of the contig. Numerous polymorphic markers had been identified within the contig, permitting the disheartening conclusion that a long region (black bar) was resistant to meiotic recombination. (C) By June 16, 1996, many of the BACs in the contig (blue bars) had been transfected into immortalized C3H/HeJ macrophages in an attempt to reveal complementation. Some of the BACs (orange)were suspected of chimerism. The red bar indicates successful, stable transfection and completion of complementation testing. The approach was to prove fruitless. (D) Gene identification proceeded throughout 1996 and until the correct gene was found. In the proximal half of the contig, five genes (and several candidate genes, based on EST homology) had been discovered by the first third of 1997. Most of these were formally discarded when marker B (orange circle, near center of the panel) was designated as the new proximal border of the contig, pursuant to the analysis of 1600 additional meioses. The B → 83.3 interval was examined in exhaustive detail by shotgun sequencing and other methods. By June 17, 1998 (E), the map had approached its final form. Candidates identified by EST homology are shown in blue; a lone candidate identified by GRAIL analysis is shown in red. The non-recombinant region is shown in black, and meiotic distances between Lps d and the limiting markers are shown in red. One by one, candidates were excluded. In general, high density sequencing (performed after light sequencing of the entire region) proceeded from the center and was executed bidirectionally. (F) Immediately prior to the identification of Tlr4, all BACs shown in blue had been sequenced to completion, and only pseudogenes had been identified, as well as a small, 5' portion of the Pappa gene. BACs (and a lone YAC) shown in red had been heavily, though not completely, covered. There were, at that stage, no longer any 'active' candidates: a most disconcerting circumstance. For historical accuracy, the maps shown in (A-F) have not been redrawn, but instead reproduced photographically from originals, so that the reader can follow their appearance as they were created in the course of the genetic and physical mapping efforts described in this paper. It is recognized that some of the details are difficult to read. Fig. 2A confinement of the locus further, this distal boundary of confinement was never to change.
Hence, by the latter half of 1994, we had reason to be pleased with our progress. We had confined the gene to an interval only 0.8 cM in size during the first year of effort. Nothing had been heard from our competitors in Canada. Perhaps they had not mapped the gene so tightly as we had been led to believe, or surely they would have cloned it by now. Perhaps they had committed mapping errors that would make it impossible for them to find Lps at all. Who knew? Putting fears aside, we pushed to cover the entire interval (which now extended from D4Mit325 to 83.3) with BAC clones. And at the same time, using exon trapping and direct selection, we began to search for genes.
THE 'SCOOP' AND THE (BIZARRE) EXCHANGE OF DATA
Alas, there are many mood swings in positional cloning efforts. The first of them hit in 1995 with the news that the gene had already been cloned! We had been beaten, it seemed, and with over a year of effort behind us, the blow was a hard one.
The word came in July 1995 from Stefanie Vogel, of whom I had inquired in yet another conversation as to 276 Beutler, Poltorak whether she knew of any progress in the field, suspecting that she herself had continued to search for the gene though she had discouraged me from beginning to do so. Unwilling though she was to provide either the name of the investigator or the gene, she intimated that the game was over: the gene had been found. She was, in fact, quite sincere in her belief, and also quite convincing.
Accordingly, I suggested that each of us might share data with the other in what would constitute a 'post-mortem' analysis of the gene that we had each striven to clone.
As we became aware, Stefanie had applied a different mapping procedure in her approach, which did not depend upon the generation of meioses, nor upon measurement of crossover frequency. Rather, she had obtained mice bearing large chromosome 4 deletions, created years earlier by other workers who had been interested in lethal mutations surrounding the b locus. By placing the deletions in trans with Lps d and determining which deletions brought about total loss of LPS signal transduction, she hoped to map the mutation to high resolution. The approach was a clever one, and ought to have worked {11}.
In the course of our discussion, Stefanie also informed us of mapping work carried out by others in which several of the markers in our critical region, invisible to us because of the particular mating combination used, had been set in rough order with respect to each other. These data, published in the recent past by Rinchik et al. 26 and by Bell et al., 27 were of considerable assistance to us.
Further, it emerged that some of the deletions that Stefanie had placed in trans with Lps d spanned our entire critical region, yet purportedly failed to abolish LPS signaling. The conclusion, were the data to be believed, would be a very strange one. Lps d , present in a single copy per genome, would be capable of supporting LPS signal transduction, while two copies were, of course, known to be inconsistent with an LPS response. This would suggest that Lps must encode a protein extrinsic to the LPS signaling pathway, but capable of modulating it.
Stefanie was kind enough to send us her primary data (as we, in turn, had sent her our map). Though the data excited our interest, we were never fully convinced by them. The range of LPS responses (as measured by TNF concentration in the blood following intravenous LPS injection) spanned three orders of magnitude, giving us concern about how robust the data could be considered to be.
In the days that followed, it emerged that early reports that the gene had been cloned had in fact been greatly exaggerated. Perhaps it was not cloned after all. In fact, probably it had not been. No, surely not; there were no data to support a chromosome 4 location of the gene. And so it went until it made sense to go back to our work as usual, unencumbered by lamentations over our perceived defeat.
REVERSAL OF FORTUNE
We returned to our work energetically, spurred on partly by concerns that not only the Canadian group, but Stefanie (and, as we then understood, her collaborators at Immunex) were trying to clone Lps. At first, we continued to make rapid progress. Our efficiency in using all of the methods required of us increased steadily. But, as time went by and as our concept of the critical region solidified, the situation began to appear more seriousthen frankly bleak.
Gradually, we became aware that the critical region was far larger than we had believed: in fact, fearfully large by the standard of successful cloning efforts pursued in the recent past. As BAC clones were 'painted' onto the framework of unique markers that we had obtained from random sequencing of the YAC clones, we naturally hoped that they would overlap with one another to form a seamless contig. But alas, they did not: disconcerting gaps remained. And these gaps were not easily covered by walking, as we had hoped and expected. Many of the BAC ends were repetitive, and to 278 Beutler, Poltorak Fig. 2F find unique sequences suitable for walking, one had to fragment the BACs, or clone large pieces of the ends. Even at that, the gaps would not close in the anticipated one or two cycles of walking. The situation was quite frustrating: we had every reason to expect that all of the gaps would close promptly in a densely marked region only 0.8 cM in length. Before long, we had acquired 50 BACs: and still, aside from coverage by YACs, the contig had not been brought to closure.
Extremely concerned at the large (and growing) physical size of the critical region, I pressed to achieve a precise estimate of the nucleotide distance across the interval. Using seven BAC clones as 'anchors', we performed seven distance measurements by FISH, hybridizing the BACs with interphase nuclei from normal mouse cells. This technique can reliably measure separation between points on the chromosome ranging from 0.2 to 1.6 Mbp. Adding distances along the contig, we found the separation between our two limiting markers to be a stunning 3.2 Mbp: an estimate consistent with that derived from pulsed-field gel electrophoresis estimates of BAC size. Quite well aware that such an interval, equal to 0.1% of the entire genome, might contain hundreds of genes, we struggled to find a means of confining the Lps locus to a single YAC, or better still, to a single BAC.
We tried to produce transgenic animals using YAC clones, in hopes of complementing the Lps defect, but were unable to achieve this, probably because neither the quantity nor the quality of YAC DNA that could be harvested from pulsed-field gels was adequate for the task. While BACs might have proven a suitable alternative, many of them would have been required to span the critical region, and we lacked the resources required to make 20 or more transgenic mouse lines.
Instead, in 52 separate cultures, we introduced every BAC in the contig (when, at last, continuity had been achieved across most of the region) into Paola's C3H/HeJ macrophages, creating stable transfectants and hoping to find one or two BACs that would restore the LPS response. Again, no success was forthcoming. Was Lps too large to fit into a BAC clone intact? We repeated the experiment with adjacent pairs of BACs, again selecting stable transfectants and checking their responses to LPS. There was no rescue of the phenotype. The technical adequacy of the approach was not entirely clear to us. While the BAC vector was detected in all stable transfectants that were produced, we could not verify the integrity of the DNA insert. And, as such, we were left uncertain that the experiment had been a valid one. At any rate, we were no further along for all of our trouble.
As a clearer picture of the spatial arrangement of the novel microsatellite markers that we had found began to emerge, we realized that a large region of the genome corresponding to the central contig seemed resistant to meiotic recombination. Seven of the new markers, arrayed across 1.6 Mbp of DNA, were invariably colocalized with one another (and with Lps) in the F2 generation. And the region wherein cross-over did not occur might actually extend far beyond the bounds of the markers that were visible to us. 'Cold spots' for genetic recombination are well known to occur in genomic DNA (as are 'hot spots'). In some instances, the choice of strains is influential, as it is well known that different species of Mus, such as Mus spretus, yield a low frequency of meiotic recombination occurring in gametes of the F1 generation when crossed to Mus musculus.
We, therefore, decided to return to genetic mapping, making a new choice of strains used in the initial cross. We instituted another cross, this time using C57BL/6 mice as the mating partner for C3H/HeJ. Back-crossing to C3H/HeJ, we genotyped 1600 additional F2 animals. Those with potential cross-overs were phenotyped for LPS response. This effort, which required several months to complete, identified four cross-overs between one of our new microsatellite markers (marker 'B', which became the new proximal border of the contig) and Lps d . In consequence, the size of the critical region was reduced to 2.6 Mbp. Our efforts had spared us the need to examine 600 kbp of DNA, but part of this had already been examined, and in any case, 600 kbp did not seem like very much {12}.
We were, in the end, forced to accept that the entire region -now 2.6 Mbp in length -would have to be explored. Never before had a specific mouse mutation been found in a critical region of such intimidating size.
THE THRILL OF THE CHASE
By the middle of 1995, recognizing that the project had grown too large for Christophe and Alexander alone, I directed Patricia (Patty) Thompson, an able technician, to join the effort full-time. Irina (Ira) Smirnova soon was asked to participate as well. Xiaolong He and Mu-Ya Liu joined the laboratory in turn, and also worked exclusively to clone Lps, as did Oonagh McNally, and my technicians Riki Alejos and Maria Silva, and a series of summer students. The final postdoctoral fellow to join the effort was Xin Du. But to her good fortune, the gene was found within only a few months of the time she entered the lab.
The project was one that called for the highest level of maturity, trust, and co-operation among workers. Each needed to pursue a different task, often for months on end, and each needed to know that the others were performing capably, lest all would suffer. All labored in the hope that, once the gene was cloned, a measure of individuality might be restored to the lab: there would be projects aplenty, I promised them. But for now, they must work selflessly, and without thought of personal reward. I do not claim that the ideal standard of conduct was achieved. There were, in fact, quarrels among personnel, and some members of the group were more highminded than others. But surely, the situation could have been far worse than it was, and reflecting upon what I asked of these people, I am much indebted to all of them.
What was our life like, then, during those next two years? It was not boring in any sense, as one might reflexively assume. It was often painful, to be sure, and there was a seemingly endless routine to follow. But it was filled with a mixture of longing, exultation, and occasionally, terror. We felt as prospectors must feel, or as gamblers must feel. Indeed we were prospecting. We searched day after day, BAC by BAC, exon by exon, clone by clone, and ultimately, base pair by base pair for something that we knew must exist, as a prospector searches for elusive gold. Always there was great anticipation over the results of the day's BLAST search, or the day's GRAIL analysis {13}, which might instantly announce the end of our quest. Was there a promising lead? A new candidate? Had a mutation been found in one of the existing candidates? On occasion, we rejoiced feeling that our goal was in sight, only to have our hopes dashed within days. Ever present was the fear that, upon opening the next issue of Nature, we would read that the gene had been cloned elsewhere, as a gambler fears the cards of those arrayed against him.
Xiaolong, Mu-Ya, Christophe, and Patty painstakingly continued to assemble the BAC contig that would sustain our search for the gene {14}. Xiaolong and Christophe trapped exons, sequencing more than 160 of them (chiefly by hand). They found many exons that arose from pseudogenes. They found many that arose from Pappa (the gene nearest Lps, as it turned out), and others that, so far as we could determine, originated from non-exonic DNA. None arose from Lps itself.
Alexander identified candidates by the independent method of 'direct selection', or 'hybridization selection', in which macrophage-derived cDNAs that could hybridize tightly to parts of the contig were eluted off, cloned, and sequenced. He examined thousands of candidates in this manner, sequencing most by hand, and finding all of the genes resident between marker D4Mit325 and B (that is to say, genes that were ultimately excluded from the contig on mapping grounds). He also found many pseudogenes within the contig proper, but not Lps itself.
Another approach pioneered by Alexander was the method of making 'repeat-free' probes from whole BAC clones. A BAC would be fragmented to produce a plasmid library of several thousand clones. These clones would then be probed using mouse CoT-1 DNA: that is, genomic DNA selected for its high content of repetitive sequence by permitting it to anneal for a brief period of time and then harvesting double-stranded forms to the exclusion of single-stranded material. Colonies that 'lit up' when probed with the CoT-1 DNA were systematically cut from the agar plate and discarded; those colonies (several hundred of them) that gave a weak signal or no signal at all were retained in order to make a complex probe. Such a probe was very specific in its ability to recognize a single BAC, and presumably cDNA derived from that specific genomic sequence. But although several cDNA candidates were identified in this manner, none proved to be derived from an authentic gene.
Mu-Ya, Alexander, Xiaolong, and Ira all cloned and rigorously examined candidates as they arose. Of the many cDNAs that were cloned, some (for example, HMG-I, KIAA0029, and TCP-I) proved to be the expressed counterparts of pseudogenes within the contig. Some sequences identified by homology (BLAST) searches against EST databases were unclonable, as they were actually genomic contaminants of EST databases. But these latter sequences were held in high regard for a very long time, as they were not mere homologs of sequences within the contig: they were perfect matches.
Throughout this period, candidate clones were tested for hybridization to Northern blots prepared from C3H/HeJ and C3H/HeN macrophage RNA on the one hand, and C57BL/10ScCr and C57BL/10ScSn macrophage RNA on the other. In performing both analyses, we reasoned that we would have a better chance of finding a null mutation. A steady supply of RNA from Chris Galanos and Marina Freudenberg abetted our efforts. Yet until the very end, no candidate showed any difference at the RNA level.
Increasingly, inevitably, we began to dream of sequencing the contig. At first, we dismissed this thought as an impossibility. We had no automated sequencer of our own, and at $35 per read, execution of tens of thousands of reads would not be feasible for us. Rather, we would sequence 'lightly' in order to find the gene. But when light sequencing did not produce the desired effect, we began to sequence more, and ever more, addicted to the data that passed before our eyes.
Sequencing eventually seemed the surest way to find the gene. If homology searching did not identify Lps, then it might well be found by GRAIL searches. Or, in the awful event that it was also unfindable by GRAIL, a doomsday scenario called for recloning the entire region from C3H/HeJ and C3H/HeN mice, and ultimately finding the mutation through comparison of the genomic sequence of the two strains.
In the beginning, all sequencing was performed by Shirley Hall, a skillful technician in the rather exorbitant Microbiology sequencing service lab at UT Southwestern. Samples were also sent to the Pharmacology sequencing service lab (which produced shorter reads, each at the slightly more bearable cost of $25). We knew that the cost of sequencing at either facility could not long be sustained and, in all, we never submitted more than 2000 samples to these facilities, pleading successfully for a modest discount based on volume. To our partial relief, it became possible to sequence for one quarter the cost ($6 per read) in a new facility run by Clive Slaughter, set up solely for the use of HHMI laboratories. But through-put was totally inadequate for our needs, and we could, in general, count on only 40 or 50 reads per week from this relatively inexpensive source. As mentioned earlier, our urgent requests for a DNA sequencer of our own were rejected by the HHMI administration. We were, it seemed, expected to clone the gene without the most essential tool that would be needed for the job. Polite inquiries were made of other faculty with sequencers in their laboratories, but we were told, also politely, that no through-put could be made available to us.
For a brief period, we entered into a collaboration with GESTEC, the genome-sequencing facility at UT Southwestern Medical Center. When for various reasons this collaboration proved unworkable, we turned to Dr Bruce Roe, Director of the University of Oklahoma Genome Center. Alexander, Betsy, and I made a 'road trip' to his laboratory in Oklahoma, where we begged for his assistance in sequencing the clones that we had produced from the critical region {15}. His promises were modest, but realistic. He agreed to help us, and through his technician, Sandra Clifton, we acquired several thousand high-quality reads over a period of 6 months. We also turned to Dr Edward Chan at the Scripps Research Institute. He collaborated with us as well, providing us with perhaps ten thousand more sequences. The remaining data were developed entirely in our own laboratory, using a sequencer that we acquired late in 1997, purchased at personal expense. Regardless of source, all trace files were sent to me by FTP, or hand carried on zip disk. From that point, all analysis took place within our laboratory alone.
The technicians of our lab, closely co-ordinated by Ira, formed the underpinning of the sequencing effort that led to the identification of Lps. They began to prepare minipreps from randomly picked libraries of shotguncloned BACs. Tens of thousands in number, the preparations were prepared by hand for the lowest possible cost. They were analyzed for quality before submission for automated sequencing, since the cost of sequencing was practically unbearable for us. A small sample of clones from each library was sequenced to assure that the complexity was sufficient to cover the BAC uniformly, and to assure that contamination by Escherichia coli genomic DNA was minimal. To their credit, Alexander and Ira grew so skilled at the construction of shotgun libraries that such preliminary tests were scarcely needed by the end of the project.
I myself co-ordinated the efforts of the group as best I could, for 'command and control' were essential to this type of effort. I began by preparing weekly (sometimes daily) editions of the genetic map {16}, and distributing it throughout the lab, that everyone might know what progress had been made. And I began to refine the computational and analytical abilities that were required for the Lps search. Into this effort, I drew Betsy Layton, whose organizational skills were far greater than my own.
As automated sequencing data became available to us, we were, at first, quite clumsy in dealing with it. It was not that we lacked comprehension of what must be done. Rather, the computational tools required for the work were not yet within our grasp.
BLAST searches were performed, against several databases (Genbank's non-redundant database, as well as dbEST, and the TIGR database (levels I and II), searching both at the level of peptide and nucleotide sequences). But, before a BLAST search could be performed, it was necessary to 'mask' sequences to hide common repeats, and to manually edit out vector sequences that occurred at the ends of reads. Sequences also needed to be sent for analysis using GRAIL, as we reasoned that Lps might never be encountered in EST databases (at that time, about 70% of human genes were believed to have EST representatives, as were about 20% of mouse genes).
Lacking a UNIX computer on which to perform such analysis, we masked and BLASTed using web servers, relying upon shared computational resources at distant locations. This was a time-consuming process. Routinely, for weeks at on end (with no respite on weekends), Betsy and I would prescreen for E. coli contaminants, edit out vector sequence by hand, cut and paste the remaining genomic sequences into files for submission to a masking server (CENSOR, maintained by Jerzy Jurka), retrieve the masked sequences, and BLAST them against three separate databases, each time at two separate levels. Often we would open 60 or 70 browser windows at once (and woefully overtaxed, our computers would occasionally crash as a result). We would await the return of data the following morning, retrieve the output files by cutting and pasting once more, and finally read the BLAST results with a word processor. We would then manually record conclusions concerning each sequence in strict tabular form in a notebook. I would dictate, and Betsy would write longhand. These books still survive, as a testament to the struggle we waged in those days. Even assembly of sequences was undertaken by hand as well, as the thencurrent version of GCG {17} had very limited alignment capabilities, and more sophisticated alignment programs were not maintained on the University VAX. Every sequence was FASTA searched against all others that had been acquired. It came as a particular struggle to align many sequences into long, contiguous assemblies by hand. We did so, however, not least because GRAIL worked better on long sequences. Moreover, such alignment was essential to give iron-clad evidence of overlap among BACs. But much time was lost because hardware and software for automated sequence assembly and analysis were not yet in place.
When the first few thousand reads did not yield up the gene {18}, when Betsy and I were physically exhausted, and when the University, in a policy shift, abruptly decided to charge us the ludicrous sum of $15,000 per month for using the antiquated computer which ran the GCG program, we concluded that we had best change our methods. The first step was to buy a computer of our own, and learn to use it to optimal effect. This we duly did, purchasing a new and, for that time, extremely powerful DEC-alpha computer at a price lower than that which was to be billed for one month's use of the University VAX {19}. I set about teaching myself UNIX and the essentials of the programming language PERL. So armed, I was able to write programs that would keep the critical region constantly under surveillance. BAC by BAC, sequences were assembled (using the miraculous programs phred and Phrap, developed by Brent Ewing and Phil Green), masked locally using the program RepeatMasker (written by Arian Smit), BLASTed, and submitted for GRAIL analysis: all automatically. Indeed, I wrote software that would even read the BLAST output files (in aggregate, many millions of lines in length by the time the contig had been heavily sequenced), informing me only when novel findings had emerged. And the search of the contig was repeated over and over, to ensure that new contributions to 282 Beutler, Poltorak Fig. 3 . Computational methods used in the cloning of Lps. All sequences generated from shotgun clones (or for that matter, from trapped exons or direct selection clones) were analyzed by recursive searches against our own, local database of existing sequences, and more importantly, examined for content of genes by BLAST searching and GRAIL analysis. BLAST searching, in particular, required lavish computational resources. It was necessary to BLAST frequently, as EST databases were in a rapid state of change. Maximum alignment of sequence was also preferable, and effective masking of common repeats was essential. To conserve time, a program (central_command.pl) was written to automate the entire process. Written in Perl, it would automatically purge newly collected data of E. coli or Saccharomyces cerevisiae contamination, maximally align it with existing sequence using Phrap, mask the sequence using RepeatMasker, and blast the masked assemblies and singlets against multiple databases. Only strong homologies would be flagged for further analysis and, at that, only novel hits were called to the attention of the investigator. The process kept the computer fully occupied, 24 hours per day, searching the contig from one end to the other. As the sequencing project neared completion, 2 weeks were required for a complete cycle of analysis to be executed. In the scheme shown, arrows indicate programs shown in ovals; boxes refer to the output product or starting material. Renn, a renaming program for file management; phredPhrap, a pair of programs, which read trace files and assemble them; RepeatMasker, a program for finding and hiding repetitive elements in DNA prior to further analysis; GCG, one of a number of programs in the GCG suite; Staden, another software suite for DNA analysis, used in solely for flat file extraction; Generunner, a microcomputer-based suite of programs used chiefly in primer design. the EST databases would not be missed {20}. Hence, through exercise of strong computational methods, we began to gain command of the situation. With some pride, I note that the programs I wrote informed us of the presence of the Lps gene the very same day it was encountered on our sequencer (Fig. 3) .
All depended, of course, upon the accuracy of our genetic mapping. Was it correct? Out of thousands of mice, we had to trust in four cross-overs observed to the left of the mutation, and three cross-overs observed to the right of the mutation. Could someone have been careless with the labeling of the mice or tubes? It was best not even to think of such matters. But had we failed to find Lps within our collection of BACs, we were prepared to extend the contig bidirectionally in order to locate the gene. There could, at this point, be no turning back.
In February 1996, 30 the Canadian group published a 'high-resolution map' of the Lps critical region{21}. Essentially the same data had been presented in abstract form at the International Mouse Genome Conference in Ann Arbor during the fall of 1995, by which time we had very distinct ideas of our own about the location of the gene and the appearance of the critical region. The Canadian group's genetic map was not wholly inconsistent with our data, although in one respect, there was a discrepancy that defies explanation to the present day. They found cross-overs (several of them, in fact) between D4Mit178 and Lps, where we never found such cross-overs, even through the analysis of 2093 mice (the total number of meioses ultimately studied by our group, which considerably exceeded the number studied by theirs [1604]). In fact, Lps does lie proximal to marker D4Mit178, and had we relied upon the data that they presented, more than half of our contig would have been discarded from consideration. In consequence, we would surely have found the gene far earlier: in fact, within a few months. But although the temptation to rely upon the data of the Canadian group was a strong one, we were too well aware of the uncertainties inherent in phenotypic assays of LPS response to do so. We chose to rely upon our own data only, and to ignore theirs, given that we could not see the raw assay results, nor assess their quality.
We were, all the while, ever more restive about the possibility that another group might find the gene before we did. Why, I wondered, need there be an absolute 'winner' and an absolute 'loser' in the game? Why not try to forge an agreement whereby we might share our data, greatly augmenting the number of meioses with which we could work, and then proceed from there? I envisioned that under such an arrangement, the 'victorious' group would include its competitors as co-authors.
In March 1997, a symposium{22} was held in St Petersburg, FL, USA {23}. Invited to speak at the meeting, I was pleased to discover that Emil Skamene was also present. I had dinner with him on the evening of March 16, and put to him the fact that we, too, were working to clone Lps. He was surprised to hear this, a fact which did not particularly astonish me, since we had not much advertised our activity and, as is usually the case with positional cloning, had not been able to publish anything. 'There is no reason for either side to "wipe out" the other', I told him, asking that he carry this message to Danielle Malo, and see whether a collaboration might be arranged between our two groups. I specifically omitted mention of the extent of our progress (beyond noting that we had mapped the gene to a region which was beneath 1 cM in size), and did not stress the scale of our commitment. He, for his part, was circumspect as well: he did not tell me anything about Danielle's work, nor did he press me for further details about our own. He genially agreed to act as a messenger. The evening was a pleasant one, and I sensed that I would have an answer soon, be it yea or nay.
An answer came within days. No, Emil told me, Danielle would not agree to a collaboration. This was for two reasons. First, she and her colleagues already had a collaborative arrangement with Millenium, Inc. {24}. And second, she believed that she and her group were so far ahead of us that it would not be worth their while to collaborate with us -'which may or may not be the case', Emil added diplomatically. I thanked him for his inquiry, told him that I understood, and that there were no hard feelings. Most assuredly, our resolve was strengthened by the message.
THE FALSE LEADS
In the summer of 1996, Christophe Van Huffel, who had spent 3 years working to clone Lps, left the lab to take a position at Millennium, Inc. Strictly honorable to our cause, Christophe informed Millennium officials that he had been working on Lps, but never divulged details of our mapping effort nor spoke of what candidates it had brought forth. More than two years later, having forgotten what they were told, the same people were surprised to see Christophe's name on our cloning papers.
At the time of Christophe's departure, we were largely occupied with the identification and exclusion of candidate genes. A battle aimed at a 'moving target' in the sense that new candidates were always being found and old ones discarded, this aspect of the project consumed a great deal of time and effort. In all, attempts were made to clone dozens of anonymous EST homologs.
The criterion for 'candidacy' was a BLAST score exceeding 10 -10 probability of equivalent match by chance alone at the nucleotide level. While this may seem a stringent criterion, those experienced with BLAST searches know that this is a rather weak level of homology. We adopted this cut-off value because we wished to have no chance of missing an unknown paralog of an existing EST, nor a mouse ortholog of a human EST.
Attempts were made to clone several dozen cDNAs based on EST hits of this sort: the exact number now eludes me, and would be difficult to determine, so numerous were the candidate sequences. We would invariably proceed by applying RT-PCR to search for the candidate mRNA, using macrophage RNA as template {25}. If this failed (and it often did), we would again use PCR to make an exact copy of the sequence under suspicion from genomic DNA. We would then use the PCR fragment to probe cDNA libraries of trusted complexity, derived from fetal and macrophage RNA.
It was at this step that a great burden would fall upon us, for 'positive' clones did indeed result from probing our libraries. In the great majority of cases, extensive sequencing was then performed, only to find that the clones were merely weak homologs of the probe rather than perfect matches. Perhaps unsurprisingly, while the most common repetitive sequences were excluded by masking, a great abundance of 'minor' or 'non-classical' repeats were present in genomic DNA. These escaped masking, and matched with modest homology to ESTs that contained rough facsimiles. The most tantalizing clones identified in the region were, by contrast, strong homologs of authentic sequences. Some generated immense excitement.
Early in 1996, through exon trapping, direct selection, and limited shotgun sequencing, we identified five authentic genes in the proximal half of our contig, which at the time, was 3.2 Mbp in length (see left center panel of Fig. 2) . These genes encoded Pappa (a plasma protease), arylacetamide deacetylase (a microsomal enzyme), and three proteins of unknown function: an paralog of Tera, a zinc finger protein with a known human ortholog, and a protein partly paralogous to astrotactin. These were duly analyzed. Three of the genes (the Tera paralog, arylacetamide deacetylase, and the zinc finger protein) were found to be identically expressed, and to have identical coding sequences in C3H/HeJ and C3H/HeN mice. But shortly, all five of these 'candidates' became irrelevant, as they were excluded from the critical region entirely by the finding that there were cross-overs between marker B (which lay distal to the genes) and the Lps mutation {26}.
Other genes soon excited our attention even more. To our perplexity, the sulfonylurea receptor (SUR) gene and the uKATP gene-encoding subunits of an ATP-gated potassium channel were found to reside within the critical region: this though these closely linked genes were believed to be elsewhere in the genome. Was the locus duplicated, and was one of these genes equivalent to Lps? It was well known that diazoxide, which causes a profound and immediate fall in blood pressure, acted on the same protein complex. Could it be mimicking the effect of LPS? Beyond its ability to induce cytokine synthesis, LPS was known to cause immediate hypotension in rabbits, by an unknown mechanism. Might this be why?
Our imaginations took flight, remaining aloft until, according to standard procedure, we had cloned and sequenced both genes from both strains of mice and found no mutation. Only then, through painstaking effort, did we realize that the BAC containing these genes was chimeric (a rather rare situation, but bound to happen when one has 66 BACs in the contig as we did by that time).
Undoubtedly the most devilish of all the false leads was KIAA0029 {27}. A protein of unknown function, KIAA0029 was also believed to be encoded by a gene unlinked to the Lps locus. 31 But we discovered its sequence within the contig, and not as a result of chimerism: more than one BAC contained the gene (or at least parts of it). As with the SUR and KATP candidates, the match was exceedingly strong.
There were two problems with the candidate. First, although it appeared to be a real gene in the sense that it had introns and was very extensive in size (spread over several hundred kbp), its 3′ end remained perpetually elusive. Search though we might, farther and farther down the contig, we could never find the end of the gene. Yet, we could not be sure that it was a pseudogene, for the length of some genes exceeds 1 Mbp. Second, upon cloning the KIAA0029 cDNA from C3H/HeJ and C3H/HeN mice, we found that it existed in multiple splice forms. Not two or three of them, but hundreds and perhaps even thousands of them.
Here, then, was a macrophage-expressed gene encoding a protein that had, at the amino terminus, a riotous assortment of shapes and sizes. Could this be the elusive receptor we sought? Might one isoform recognize endotoxin, while others sensed different microbial products? Here, we considered, might be the mechanism by which the innate immune system generated receptor diversity. Alternative splicing acted to achieve it, rather than the genomic re-arrangements that were responsible for immunoglobulin diversity. The possibility was breathtaking. The problem was simply to identify the unique splice form missing in C3H/HeJ mice, but present in C3H/HeN animals.
During much of 1997, Xiaolong, working alone, sequenced hundreds of cDNA clones encoding KIAA-0029 from both strains, searching for the elusive splice form that was missing from the mRNA template of C3H/HeJ mice. In the end, it simply was not there. Moreover, FISH studies and Southern blots suggested that the presence of the gene in the critical region might well have been an artefact of the cell line used to produce the BAC library, for in DNA obtained from primary cells of mice, we could find no evidence of a second locus. Wistfully, we returned to the hunt.
It bears mention that during those lonely years of searching, we had been written off by many of our colleagues, who believed that we would never find the gene. Support from Bob Munford was unending, however. With genuine interest, he would visit us now and again, inquiring about our progress, sharing our excitement as new candidates came into view, and offering encouragement as each candidate was discarded in turn. Moreover, he was a reliable source of detailed historical, structural, and biochemical information pertaining to LPS, having worked in the field even longer than we, and from a very different angle.
As to HHMI, there was the implicit message that if we had not identified the gene by the next review (firmly scheduled for April 1998), our support would be terminated. As the deadline approached, tension grew. There were some who urged me to stop working on Lps to the exclusion of other projects. 'Diversify', they said, 'it is your only hope! Then you will have something else to talk about in April'. I rejected the suggestion, well meant though it was. First of all, a substitute presentation would be of no help. HHMI demanded the gene and nothing else would do {28}. Second, there was no time for something 'new' even if I had wanted to change directions. Third, and foremost, the entire lab (myself included) had become so passionately devoted to finding the gene that switching goals was unthinkable. We would stay the course, come what might.
THE PARALLEL RISE OF THE TOLL-LIKE RECEPTORS
It did not escape our attention that a group of orphan receptors, identified as EST homologs of the Drosophila Toll protein {29}, were attracting notice because they were capable of activating NF-κB translocation in mammalian cells and, hence, seemed to be involved in inflammation. The first such example was reported by Medzhitov and Janeway in 1997. 33 A chimeric homolog of a protein known as h-Toll (later TLR4) could activate NF-κB signaling when expressed in mammalian cells. The story had begun to influence the LPS field.
In February 1998, Richard Ulevitch called me from The Scripps Research Institute to ask whether I had encountered any Toll-like receptors in the critical region. No one knew better than I that we had not, this though much of the contig had now been densely sequenced. I replied as much, emphasizing that I could not exclude their presence with certainty, as the most proximal and distal regions of the contig had not yet been sequenced heavily. He went on to inform me that he had heard presentations suggesting that one member of the Toll-like receptor family, TLR2, was capable of transducing the LPS signal. Furthermore, another member of the family, TLR4, was thought to be linked to human chromosome 9q, and hence, perhaps, mouse chromosome 4. Would I check again? I did so immediately with the anticipated result: Tlr4 was not represented among the sequences that we had so far acquired.
Linkage data {30} concerning five of the Toll-like receptors were published by Rock et al. in January 1998. 35 The candidate in question, Tlr4, had been assigned to human 9q32-34, an enormous cytogenetic interval (see Fig. 4 ). This position might place it in the Lps critical region, but the chances were far greater that it would not. The mouse chromosome map may be superimposed upon the human chromosome map so as
The search for Lps: 1993-1998 285 Fig. 4 . Where was the human homolog of Lps? At the inception of the cloning project, and indeed, until the very end, the location of the human homolog of Lps was unknown. Mapping work in the mouse had some years earlier placed a series of genes surrounding Lps in a precise order: viz. Tal2→Orm1→Hxb→Pappa→b→Ifa. The same genes were known to reside on human chromosome 9. However, an ancestral breakpoint was located between Pappa and b (or its human equivalent TYRP1), so that the order of human genes was: TAL2→ORM→HXB→PAPPA (on 9q, proximal to distal), and TYRP1→IFNA (on 9p, distal to proximal). Fairly early on in the course of our mapping work, it became clear that Lps was proximal to b. Subsequently, it appeared likely (and ultimately, almost certain) that Lps was distal to Pappa. Hence, the probable order: Tal2→Orm1→Hxb→Pappa→Lps→b→Ifa. The breakpoint was located between Pappa and b. But on which side of Lps did it occur? If the breakpoint were proximal to Lps, the human homolog would be on 9p. If the breakpoint were distal to Lps, the human homolog would be on 9q. No clear preference could be given to either possibility, as the Lps critical region was 2.6 Mbp in length, and the distance between 83.3 (the distal point of confinement) and b was unknown. As such, the assignment of human TLR4 to the cytogenetic interval 9q32-34 (itself an enormous interval, equal to approximately half the size of mouse chromosome 4) was less meaningful than is generally understood.
to yield a rough estimate of the location of mouse genes, given that the location of the human gene is known (and vice versa). But in the case of Lps, which had clearly been mapped to mouse chromosome 4, the location of the corresponding human gene was not clear. An ancestral breakpoint in the mouse:human homology map occurred at an unknown position, between the Pappa locus (which was proximal to Lps) and the b locus (which was distal to Lps). As a result, human Lps might be expected to lie either on chromosome 9p or on 9q, the probability of each location being equal to the other (Fig. 4 ). If the former location applied, TLR4 would be excluded as the human equivalent of Lps. If the latter location applied, TLR4 would reside within a zone perhaps 20 Mbp in size, within which Lps, by then confined to a 2.6 Mbp interval, was also present.
While we did not ignore the possibility that TLR4 was the human equivalent of Lps, neither, at this stage, did we drop all else and rush to clone Tlr4. The reader may reasonably ask why we did not. In the course of any positional cloning project, innumerable 'tips' are offered, all of which may ultimately prove incorrect. We ourselves had already received many well-meant suggestions. Lps might be an interferon-like molecule (or so the suggestion ran at first), because interferons could enhance the LPS response, and the interferon-α/β cluster was just a short distance down the chromosome. 36 LCK was important in activating lymphocytes stimulated with antigen, so might not HCK, which had been mapped to mouse chromosome 4, be encoded by Lps? Biological studies had suggested that c-fyn or c-lyn might be the protein. Atop the p38 pathway in yeast was a histidine kinase: by implication, Lps might encode a similar protein. Or perhaps Lps was an isozyme of PKC. Or a GTP binding protein. 37 Or a vesicular transport protein, 38 as suggested by others. To all who came forward, we offered our vigilance, but taxed as we were, we could not rush to investigate each suggestion made, however logical it might seem.
Beyond this, the localization data for TLR4 were made using metaphase FISH, and were very imprecise. The size of the region to which mouse Tlr4 could be assigned was immense. 20 Mbp of DNA means a region containing up to 1000 genes. Such loose localization further presumed that mouse Tlr4 was on chromosome 4 at all (and as just mentioned, the chances of this were no better than 50%). By contrast, our contig was only 2.6 Mbp in size, and 70% of it had been very well explored. In this context, it made no sense to search for Lps based on low resolution comparative mapping data, but rather to keep focused on the objective of finding every gene that remained within our interval.
Evidently, others felt the same way. No laboratory plunged into a search for the mutation based on the evidence at hand, or if they did, failed to do so with the conviction required to find a mutation. And there were those who discounted the likelihood that Toll-like receptors would transduce the LPS signal at all. Chaudhary, who was among the first to clone two of the Toll-like receptor cDNAs, 39 spoke with me in my office in the summer of 1998. Asked whether he thought that the LPS receptor might be a member of the family, he expressed his doubts, demurring that such receptors were known to convey the IL-1 signal, but that the nature of the IL-1 signal was quite distinct from that of LPS.
THE FURTHER EVOLUTION OF THE TOLL-LIKE

RECEPTOR STORY
Suspicions concerning the role of Toll-like receptors in mammalian innate immunity did not end with speculation only. Independently, workers at Genentech (led by Paul Godowski) and Tularik (led by Michael Rothe) began to examine the question of which microbial products, if any, might trigger a Toll-like receptor response. New to the LPS field, both groups designed an assay system which stood a chance of working, but one which was neither properly controlled nor physiologically sound. By the summer of 1998, both groups were claiming that transfection-based expression of TLR2 and CD14 in 293 cells conferred LPS responsiveness to those cells, ordinarily indifferent to LPS. TLR4 transfection was without comparable effect. The conclusion drawn was that TLR2 acted as the LPS signal transducer. These stories were, in total, the product of a system artifact, that diverted attention from the true conduit for LPS signaling for the next 18 months. To some extent, they still cause confusion today {31}.
What were the problems with the approach? First, an unmeasured, but certainly unphysiological level of TLR2 expression was elicited by 293 cell transfection. Second, the concentrations of LPS used to evoke a response were enormous, and the presence of contaminants could not be excluded. Third, a reporter construct was used to monitor NF-κB signaling, surely one of the least specific endpoints that might have been chosen. Fourth, there was no standard of comparison against which to judge 'rescue' of the LPS response: how intense a response was generated, and with respect to what? The parent cells had no response at all. The Genentech group further reported that LPS could 'bind' directly to TLR2. However, they showed no evidence that the binding was either avid or specific.
Godowski's group published their findings in Nature on September 17, 1998 {32}. 40 An accompanying Editorial ('For whom the bell Tolls'), written by Craig Gerard, raised the possibility that Tlr4 might be the product of Lps. 42 In fact, he had telephoned me some weeks earlier, asking whether I though this might be so. In reply, I told him (as I had told Richard Ulevitch before) that Tlr4 had not been discovered in our contig, the sequence of which was by this time was more than 90% complete. He, in turn, wished me well, saying that he hoped we would soon find the gene.
Within days, his hope (and ours) became a reality.
THE HILLARY STEP
In April 1998, I presented our work to the Scientific Advisory Board of HHMI. It was my feeling that I made the best presentation that I possibly could, emphasizing the vast territory we had covered, and the likelihood that the gene would be encountered soon. Although several of the distinguished scientists on the review committee seemed to appreciate both the difficulties and importance of our work, the view that my funding should be terminated prevailed, a decision which was formally communicated to me only in July, 1998. There was, it was emphasized, no possibility that funding would be restored even if we found the gene. The decision was final. This seemed a harsh blow, particularly in view of the fact that HHMI prided itself on supporting investigators who pursued tough, long-term projects. They had, in fact, seen other (far more lengthy) positional cloning projects through to completion. But ours was not to be one of them. The news, which I announced to the lab in a sober meeting the following week, was unsettling. Though we were to receive two more years of support prior to a cutoff of funding, the psychological impact of the rebuke was palpable.
The summer of 1998 was, without doubt, the most stressful of the entire project, for hope of finding the gene diminished with every passing day, and there was no hiding the fact that this was so. Mu-Ya soon left the lab, and after her, Xiaolong. I myself was discouraged, given that most of the critical region had been explored. As we approached the limiting markers, B and 83.3, there was simply less and less room for optimism. Nadia Krochin, long ago a student of mine, assured me otherwise. Referring to an account of the ascent of Mount Everest {33}, she drew analogy to the 'Hillary Step', an obstacle immediately beneath the summit: one that is not formidable in itself, but formidable to those who have just climbed 98% of Mount Everest. 'You are at the Hillary Step', she assured me. But after 5 years, with the vast majority of the contig already analyzed ad nauseam, who could be so certain where the summit lay?
The defining moment came at 9:30 pm on September 5, 1998 . While working at the computer in my study, reviewing the day's BLAST results from the BAC I17 (one of the most proximal in the contig), I was stunned to see a powerful match with the human TLR4 sequence. In a few minutes, I saw a second hit (a third was to follow the next day). Tremulous with excitement, I called Alexander. I was, of course, nearly certain that Tlr4 was, after all, Lps. There was no time to be lost in proving that this was the case.
SANTA FE, GARMISCH, DENVER AND JERUSALEM
'Don't jinx it, Bruce', Ira admonished me the next morning. She, Alexander and I knew that this must be the gene. But in seeing so many other candidates evaporate, the strongest rationalist grows superstitious. I must not talk too much or too loudly about having found the gene, lest this candidate go the way of the others.
During the night, I had designed primers to amplify the mouse Tlr4 cDNA based on the human sequence, as well as other primers to amplify the mouse Tlr4 gene {34}. The primers were ready by afternoon. The cDNAs were amplified from C3H/HeJ and C3H/HeN macrophage mRNA. The bands, 3.6 kbp in length, were sonicated and shotgun cloned, for this was our way of acquiring sequence {35}. Simultaneously, I telephoned Ed Chan in La Jolla, and redirected his effort, asking him to abandon sequencing of the distal contig (from which he had been sending us excellent data during the past months), and to concentrate instead on BAC I17 {36}. Dale Birdwell, our sequencing technician, also abandoned all work except that related to Tlr4. By September 13, we had executed 100 reads from the C3H/HeJ cDNA, deeply covering every base pair within the sequence. C3H/HeN had also been shotgun cloned, and minipreps from this vital congenic control were queued for sequencing with the most urgent priority.
By that time, I had left town, however, traveling to a meeting in Boston. During the flight, and while in hotel rooms, I wrote a manuscript detailing the genetic and physical mapping of Lps, pointing out that Tlr4 was the sole candidate in the critical region, and suggesting that it was, in fact, the relevant gene. The paper was submitted to Blood Cells Molecules and Diseases, a journal that provides extremely rapid publication, first on the Web and also in printed form. The paper would stand as the underpinning of the final, definitive paper that we hoped to publish, describing the mutation {37}.
I then traveled directly to Santa Fe, NM, USA. Several months earlier, I had agreed to speak at the International Endotoxin Society meeting, which was held on September [12] [13] [14] [15] 1998 . Alexander had been present at the meeting since the start; I myself arrived midway through. Also to be present was Danielle Malo, who had originally been scheduled to speak about her own positional cloning effort, but who had decided not to at the last minute, citing restrictions imposed by her collaborators at Millennium, Inc. Should I discuss our finding of Tlr4? Or should I remain silent? It was a question that Alexander and I debated, and one which we occasionally debate even now. A slide was prepared just in case.
Did Tlr4 in fact have a mutation? From our hotel room, Alexander and I analyzed the sequences together. We did not have the benefit of the program consed {38}, which produces a superb graphic image of sequences in alignment with one another. Nor did we have a printer. Our telnet connection, via a modem link with America Online, was agonizingly slow. We did, indeed, see the mutation, but we were not sufficiently confident to declare its authenticity without seeing the trace files themselves. And this we could not do without access to an X-windows terminal.
At the Santa Fe meeting, there was much discussion of TLR2 and its purported role in LPS signal transduction. We, for our part, knew already that if Tlr4 was equivalent to Lps, the claim that TLR2 could transduce the LPS signal had to be wrong {39}. The data did not allow for two independent signal transducers. If TLR2 made a substantial contribution to LPS signaling as implied by transfection studies, this contribution would be evident in mice that lacked a functional Tlr4. But C3H/HeJ mice were profoundly unresponsive to LPS; hence, any independent contribution by TLR2 would necessarily be miniscule. This did not disallow a requirement for TLR2. But neither was there any evidence for such a requirement {40}.
Alexander and I had dinner with Jiahuai Han the evening before I was scheduled to speak. We confided in Han, and asked his opinion of what course to pursue. Han first advised that I should not say that the gene in our critical region was Tlr4; only that it was 'a Toll-like receptor'. The advice might have been wise, but the slide said 'Toll-4'. And besides, as I assured him, it was Tlr4. Further, our mapping paper had been accepted for publication, and was scheduled to appear the very next day, immutably establishing our priority. In the end, I decided to disclose what we knew to be true: that Tlr4 was the sole candidate in the critical region, but I would firmly abstain from discussing the mutation or indeed, any data pertaining to sequence, which we needed to examine more closely.
Supporting the argument that Tlr4 was indeed the LPS signal transducer, I pointed to the fact that a human patient with a severe immunodeficiency was known to exhibit co-resistance to LPS and IL-1. 44 The fact that Tlr4 and IL-1R are receptors that have similar cytoplasmic domains is concordant with this observation to the extent that a common transducer (for example, MyD88) might act to propagate the signals of both molecules. I was, I believe, the first to grasp the meaning of the mutation, although to the present day, it has not been explained in molecular terms.
The immediate reaction to my presentation was largely positive. The majority of participants at the meeting felt that the story was over, and issued warm congratulations. These we accepted with reservation, for as I had stressed, the story would end with the mutation itself, though its elucidation was now only hours away. There were other reactions as well. Through another conferee, word reached us that Danielle Malo had categorically denied that Tlr4 was the gene; she knew that it was not, we were told. The news stirred a brief wave of self-doubt. Could we have been carried away by our enthusiasm? If Danielle knew that Tlr4 was not the correct gene, perhaps we had made a dreadful mistake. But no, Tlr4 must be the holy grail we had sought.
Before leaving Santa Fe, I spoke quietly with my friends Chris Galanos and Marina Freudenberg who, as already mentioned, had maintained and studied the C57BL/10ScCr mouse for many years. On several previous occasions, when we had felt excited about a particular candidate and felt that victory was near, they had provided us with mRNA from the C57BL/10ScCr animals in order that we might check our results. Now, feeling certain that the moment of truth had arrived, we needed to look at both C3H/HeJ and C57BL/10ScCr strains, lest any mutation observed in the former be dismissed as a neutral polymorphism, however closely related C3H/HeN might be. Our supply of both RNA and DNA had been exhausted. Could I have some fresh RNA and DNA from these mice? They immediately assented that I could, and sharing our sense of urgency, promised to prepare it post-haste.
Returning from Santa Fe, Alexander and I were met by Ira and Betsy at the airport. We drove first to a Mexican restaurant for a Margarita to calm our nerves. That accomplished, we returned to the lab, where our sequences awaited definitive examination. As we were well accustomed to doing, we assembled the sequences using the phredPhrap program; then searched for mismatches between the C3H/HeJ sequence and sequence that we had, by that time, established for the 129/J strain (the source of the BAC library). As already mentioned, the sequences from C3H/HeN mice had not yet been completed, and for technical reasons, had been delayed for two days.
Within minutes, we had confirmed the presence of one and only one mismatch: the substitution of an A in C3H/HeJ for what had been a C in the reference strain. This base transversion would specify a missense mutation in C3H/HeJ mice, converting an evolutionarily conserved proline to a histidine. Although very hopeful that this was, indeed, the mutation, we remained unconvinced pending completion of the corresponding C3H/HeN sequence. To guard against further delay, primers were immediately prepared to confirm the mutation in C3H/HeJ genomic DNA (and to determine whether it was absent in C3H/HeN genomic DNA). On Friday, September 18 the uniqueness of the mutation was duly confirmed by Alexander, who stood watching, rapt, as the gel image was generated on the monitor. Only C3H/HeJ mice, and not C3H/HeN animals, displayed the critical transversion.
Still we truly could not believe our eyes. For days, each of us would quietly walk to our X-windows monitor to review the sequence on the screen. Even after the monitor screen had been photographed, there was a lingering sense that the mutation might somehow fade away.
With the arrival of RNA and DNA from the C57BL/10ScCr mice, we attempted the same shotgun cloning exercise. It did not work: the cDNA could not be amplified, nor could discrete segments of the gene (for which we had now developed a series of primers) be amplified from the genomic DNA of these animals. Suspecting a deletion, we performed a Northern blot. There was no Tlr4 message to be seen. In the control strain C57BL/10ScSn, the cDNA was amplified, and was found to have a normal sequence. Hence, one could no longer credibly argue that the mutation in C3H/HeJ animals had been a neutral polymorphism.
On September 30, without further ado, we submitted our paper to Science {41}. Alexander disclosed the mutations at the International Mouse Genome Conference in Garmish on September 30. Danielle Malo did not attend the meeting. However, Karen Moore, a senior scientist from Millennium, Inc., and a collaborator in Danielle's Lps cloning effort, sat attentively -and silently -in the front row. The mutations stood out clearly for all to see.
On October 29, Alexander spoke again, this time in Jerusalem, at the International Cytokine Symposium, while on the same day, many time zones away, I addressed the American Society for Human Genetics in Denver, in a special session devoted to late-breaking news. More than 3000 people were in attendance. The race was over, and we had won {42}.
THE AFTERMATH AND THE TOLL-LIKE
RECEPTORS TODAY
At present writing, 19 months have passed since the Tlr4 mutations were identified. In the interim, a number of outstanding publications have deepened our understanding as to how Tlr4 and its paralogous relatives work. Akira and colleagues discovered that Tlr2-deficient mice were entirely competent to respond to LPS, but deficient in their responses to peptidoglycan and bacterial lipopeptides. 43, 45 They also showed, for the first time, that Tlr4 mediates the lipoteichoic acid signal in addition to the LPS signal. 43 Meanwhile, we ourselves 46 and, independently, Lien and coworkers 47 demonstrated through genetic complementation studies that LPS undergoes close physical interaction with Tlr4 as a necessary step in signal initiation. Unlike the situation in Drosophila, vis a vis fungal recognition, there is no proteolytic activation step involved in LPS recognition. During 500 million years of evolution, substantial changes seem to have occurred.
The overall impression gained is that each Toll-like receptor is oligospecific, interacting with a few broadly expressed microbial products, and doing so directly. Nine Tlr cDNAs have now been cloned. 48, 49 A tenth is believed to exist based on homology searches against genomic databases. The importance of pathogen recognition by Toll-like receptors is suggested by a human mutation, 32 mentioned previously, that seems to globally depress signal transduction through the Toll-like domain. Such a mutation causes severe immunodeficiency. It might be expected that knockout mutations of MyD88 -known to be a transducer of Toll-like receptor signaling -will be shown to cause immunodeficiency in mice. At the structural level, progress has been made as well. Shimazu and colleagues 50 identified a small, secreted protein (MD-2) that interacts with Tlr4 on the cell surface, and apparently abets signal transduction initiated by LPS. Will knockout mutations of MD-2 influence the endotoxin response? The world eagerly awaits the answer.
A certain amount of confusion has grown as well. For fully a year following our identification of Tlr4 as the relevant gene at the Lps locus, there was a vexing tendency to refer ambiguously to the role of 'the Toll-like receptors' in LPS signaling: as though Tlr2 and Tlr4 had been shown to have equal standing as transducers, each claimant having been reported in a prominent journal. There was even discussion as to whether the human Tlr2 protein might function as the LPS transducer, while the mouse Tlr4 protein fulfilled the same function. However, the preponderant opinion now holds that Tlr4 acts as the sole transducer in all mammalian species, at least where enteric LPS is concerned. A somewhat eccentric challenge to the role of Tlr4 arose late in 1999 and was reinforced early this year with the untenable post facto claim that Ran/TC4 -and not Tlr4 -is actually the product of the Lps gene. 51, 52 Yet Ran/TC4 is neither linked to mouse chromosome 4, nor is it actually mutated in C3H/HeJ mice {43}.
Other publications that emerged close on the heels of the cloning work are also curious, and have raised doubts among workers familiar with the genetic basis of endotoxin resistance as we now understand it. One example concerns the work of Vogel and colleagues, 53 who as already mentioned, had developed data suggesting that hemizygosity for what is now known to be the Tlr4 Lps-d allele was compatible with LPS signal transduction. The idea was tenable at the time -before it was demonstrated that the C57BL/10ScCr defect was a null allele of Tlr4 {44}. It had previously been shown that the C57BL/10ScCr mutation is purely recessive to the wild type allele, and also that crosses between C3H/HeJ mice and C57BL/10ScCr mice yield animals that are profoundly insensitive to LPS. It seems highly improbable that a much larger deletion, placed in trans with the Tlr4 Lps-d allele, would have a different effect.
Whither the future of Lps? Several lines of investigation immediately present themselves. First, we do not fully understand how Tlr4 signals, nor are we certain about the full complement of proteins that participate in the signaling complex. The structural studies of Tlr4 that are under way in many laboratories are, therefore, interesting indeed. Second, there is much curiosity about what other members of the Tlr family do. What microbial ligands do they bind? Are they involved in development as well? Third, the regulation of Tlr4 (and its paralogs) is a matter of considerable importance. Both the expression of Tlr4 and post-translational modifications of the protein may govern its signaling potential. And finally, the question arises: do mutations of TLR4 create important phenotypic effects in humans? Are some patients with Gram-negative sepsis functionally equivalent to C3H/HeJ mice?
Some of these questions have been answered already, at least in part. And it may be said that the general view of innate immune sensing has been advanced in a dramatic fashion pursuant to the discovery that Lps and Tlr4 are one and the same. Far better than before, we now understand how macrophages 'see'. . This news was unsettling indeed, and prompted discussion as to whether we ought to give up rather than race against such a juggernaut). {6} The web was then rather new, if the reader is able to recall such a time. C. Victor Jongeneel, a friend and colleague, advised me to have a look at it, instructing me to acquire the program 'Mosaic'. {7} Ultimately driven to a state of anguish by thirst for sequence, I purchased a used and somewhat outmoded ABI model 373 sequencer at personal expense, persuading HHMI to pay for an upgrade to 64 lane capability. The machine was used to extraordinary effect, and ultimately won the battle for us: the trace files that contained Tlr4 sequence were among the last of the many thousands of files that it yielded. {8} Thenceforth known to us as 'the Canadian group'. {9} b, for brown coat color, encodes the tyrosinase-related protein (in humans, TYRP1). It is not to be confused with the marker B, which later denoted the proximal margin of our contig. In 1993, it was not known whether Lps lay proximal or distal to b.
NOTES
{10} On average, 493 meioses might permit confinement to 0.2 cM, given infinite marker density, or to well under 1 cM, given the density of markers that were actually present. {11} It did not, for reasons that remain unclear, at least to us. {12} Before the end of 1996, several genes had been identified in the proximal contig, within a region between markers D4Mit325 and B. These genes, encoding an astrotactin paralog, a zinc finger protein, arylacetamide deacetylase, and a Tera paralog, were all discarded as candidates when it was determined that all lay proximal to marker B. As such, all lay outside the bounds of the final critical region. The Canadian group, confused by errors in physical mapping, found two of these candidate genes, but failed to exclude them from consideration on the grounds of genetic mapping. Hence, their erroneous conclusion that several genes lie in close proximity to Tlr4 and actually surround it. 28, 29 {13} GRAIL is an ingenious gene-finding program, devised by Richard Mural of the Oak Ridge National Laboratories. It searches uncharted stretches of genomic DNA, identifying probable exons with remarkable sensitivity and specificity. In its X-windows format (X-GRAIL), a 'picture' of genes is actually created. I first encountered GRAIL when its capabilities were described by Mural at the 1996 meeting of the Mouse Genome Conference in Paris. {14} It was not completed by the end of the project, at which time a minute gap in the BAC contig remained, covered, however, by a YAC. {15} October 23, 1997. {16} Some 50 dated maps survive. They tell the story of the cloning effort as it unfolded week by week. {17} GCG, Genetics Computing Group, makers of a suite of powerful, useful programs for genetic analysis. We made constant use of GCG programs during the course of the project, and chained them together with PERL scripts. Lynn Miller and Eric Cabot were immensely helpful to us in developing these programs to a state of optimal performance. When their own programs were not adequate for our needs, they were quick to direct me elsewhere. {18} Ultimately, 40,000 reads were required to find Lps. {19} For once, HHMI was generous with us, and did provide us with money for the purchase of the DEC-alpha. {20} By the end of the project, the DEC-alpha computer no longer seemed so fast. Two weeks of BLASTing were required to search the contig from one end to the other. This resulted partly from the fact that NCBI had notified us that we had become a burden on their computers, and they would no longer permit us to BLAST on their server; hence, our local computational power was largely absorbed with the task. {21} It later appeared that they had published what data they had at the time out of fears engendered by the spurious report that Lps had already been cloned.
{22} Molecular Mechanisms of Host Cell Interactions in Periodontal
Disease. {23} Linked in memory with this meeting was another event, held 6 months later: the 11th International Mouse Genome Conference, which also took place in St Petersburg, FL, USA (October 12-16, 1997). Xiaolong He and I attended this meeting, and learned that yet another positional cloning group had made substantial in-roads into the Lps problem. This was the group of David Schwartz and his coworkers at the University of Iowa, who mapped the gene using a unique and seemingly effective in vivo assay, which entailed the measurement of pulmonary airway resistance induced by intratracheal administration of LPS. They had, by that time, assembled a contig that overlapped with ours through much of its length. {24} A company founded on positional cloning technology, and endowed with an awe-inspiring sequencing capacity.
{25} It was taken as an article of faith that Lps would be expressed by macrophages, since these cells so clearly respond to LPS. While there was an outside chance that even this assumption would prove erroneous, it did, in the end, prove to be true. {26} The Canadian workers apparently clung to three of these candidates to the bitter end, deceived by physical mapping errors and unable to find the correct gene. {27} An EST clone, isolated and sequenced in Japan. The KIAA designation now pervades Genbank, and is well known to positional cloners. {28} 'It is imperative that you find the gene prior to your next review', James Gavin (Senior Scientific Officer for HHMI) had warned me en passant, while refusing a minor request made in 1997. {29} In 1996, Jules Hoffmann and his co-workers had shown that the Drosophila Toll protein is required for antifungal responses of adult flies, as its activation led to the synthesis of Drosomycin, an antifungal peptide. 32 On this basis, it was believed that Tolllike receptors might be important in mammalian innate immunity, but their exact role remained unknown. {30} Partly correct and partly incorrect. Rock et al. accepted the FISH assignment of Taguchi et al. 34 in averring that TLR1 (earlier known as KIAA0012) resides at human chromosome 4p14, where in fact TLR1 is extremely similar to TLR6 and, according to current human genome sequencing data, both genes reside on chromosome 6. {31} The initial retreat from the position that TLR2 was the LPS receptor began with the demonstration that knockout mice lacking Tlr2 responded perfectly well to LPS. But the groundless belief that TLR2 might be 'sufficient' for LPS signaling died a much slower death, surviving in some circles even today. {32} Rothe's group published substantially similar data later in the year. 41 {33} Jon Krakauer's narrative, Into Thin Air (Random House, 1998). {34} The mouse Tlr4 cDNA had not been cloned. A single EST representative of mouse Tlr4 was present in dbEST, but it would not suffice to cover the coding region. To our good fortune, however, both ends of the Tlr4 coding sequence had been struck by sequences in the shotgun clones. Hence it was possible to amplify the entire coding region immediately. {35} Shotgun sequencing is little used by laboratories that have not had experience in genomic exploration. But it is surely the most accurate and most rapid means of acquiring sequence, in that dozens of overlapping reads define the DNA fragment under analysis when assembled together using a program such as Phrap. {36} Within a few days, it was determined that BAC C16 contained all of the Tlr4 locus, while I17 contained only part of it. As such, the orientation of the gene along the chromosome was clear to us. {37} The mapping paper was published on September 15, 1998, barely anticipating the TLR2 paper of R-B. Yang et al., and the accompanying editorial of Craig Gerard, which appeared in Nature two days later, as already described. {38} Software written by David Gordon, at the University of Washington Genome Center. {39} A fact clearly declared in our Science paper of 1998. 2 {40} The possibility that TLR2 might be required for LPS signaling was formally excluded by knockout work, published in 1999. 43 {41} It appeared in print on December 11, 1998. {42} As mentioned earlier, positional cloning is a winner-take-all game.
Nonetheless -and despite the fact that the mutations had by that time been reported at three international meetings -Malo and her colleagues later published some of the same conclusions about Lps as we. They submitted their manuscript to the Journal of Experimental Medicine on November 25, 1998, nearly two months after our disclosure of the mutations in their presence at Garmisch. In doing so, they omitted mention that the mutations had already been found by our group. 28 The confirmatory character of the paper, which appeared in print the following year, was ultimately acknowledged by the authors themselves. 29 {43} These papers reflect the recurrent claims of Wong, Sultzer and colleagues pertaining to the GTP binding protein Ran/TC4, first reported to rescue the LPS-unresponsive phenotype in 1996. These authors maintained that they had identified a mutation in the 3'-UTR of the C3H/HeJ Ran/TC4 gene. Such a mutation, which causes no coding change, would not be likely to exert any effect. Moreover, we have been unable to confirm the existence of the base substitution in question (Poltorak and Beutler, unpublished data). Further, Ran/TC4 is predicted to reside on mouse chromosome 17, based on interspecific comparisons of gene location. {44} It is now known that the mutation is a circumscribed deletion involving all three exons of the gene. 54 
